Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: AbbVie, Bavarian Nordic, GTx - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2016" drug pipelines to their offering.

The report provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope:

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • The report reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report reviews key players involved Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

Companies Mentioned Include:

  • AB Science SA
  • AbbVie Inc.
  • Adamis Pharmaceuticals Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • ATLAB Pharma SAS
  • Bavarian Nordic A/S
  • BIND Therapeutics, Inc.
  • Boehringer Ingelheim GmbH
  • Emergent BioSolutions Inc.
  • Glactone Pharma AB
  • GlaxoSmithKline Plc
  • GTx, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • UbiVac, LLC
  • Viralytics Ltd.

For more information visit http://www.researchandmarkets.com/research/7s43w8/metastatic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716